

SYNTHESIS, ANTITUMOR ACTIVITY AND FORCED DEGRADATION OF ACYLHYDRAZONE BENZOXAZOLONE DERIVATIVES

Petra Kovačec Slukan^a, Leon Rakić^a, Ana Zagorec^a, Leona Čakić^a, Dragana Mutavdžić Pavlović^a,
Leentje Persoons^b, Dirk Daelemans^b, Tatjana Gazivoda Kraljević^a


^aUniversity of Zagreb Faculty of Chemical Engineering and Technology, 10000 Zagreb, ^bKU Leuven, Rega Institute, Leuven, Belgium

BACKGROUND

The benzo[d]oxazol-2-one core represents a promising scaffold in medicinal chemistry due to its favorable physicochemical properties and bioisosterism with purine DNA bases.[1] Furthermore, acylhydrazone derivatives exhibit a wide range of biological activities including antitumor, antibacterial and antiviral effects, owing to the bioisosteric hydrazone subunit of the amide bond, making them promising candidates for modern drug design.[2]

SYNTHESIS

The synthetic route involved cyclization of 4-substituted 2-aminophenols using 1,1'-carbonyldiimidazole to afford 5-substituted benzo[d]oxazol-2-ones **1–4**, which were then subjected to base-mediated alkylation with methyl chloroacetate to give the *N*-alkylated derivatives **5–8**, followed by reaction with hydrazine hydrate to afford the corresponding *N*-hydrazides **9–12**. The target acylhydrazone derivatives **13–54** were synthesized as *Z*-isomers *via* a mechanochemical approach involving the reaction of the benzoxazolone *N*-hydrazides **9–12** with various aromatic aldehydes using glacial acid. In addition, a tricarbonylrhenium(I) complex **55** of a selected acylhydrazone ligand **34** was successfully prepared with an addition of Et₃N.



STRUCTURAL CHARACTERIZATION BY NMR




Figure 1. Compared ¹H- and ¹³C-NMR spectra of compound **34** and complex **55**

Figure 2. NOESY-NMR spectrum of compound **34**

BIOLOGICAL EVALUATION


The *in vitro* antiproliferative activity of acylhydrazone benzoxazolone derivatives **13–54** was assessed against nine human tumor cell lines, with etoposide and nocodazole used as a reference compounds, and on normal cells PBMC to determine selectivity (Table 1).

Table 1. *In vitro* antiproliferative activity of compounds **13–54**

COMPD	IC ₅₀ / μM								
	Capan-1	HCT-116	LN229	NCI-H460	SH-SY5Y	HL-60	K562	Z138	Molt-4
13	>100	>100	58.6	>100	n.d.	>100	>100	>100	>100
14	>100	>100	83.4	>100	n.d.	>100	>100	>100	>100
15–16	>100	>100	>100	>100	n.d.	>100	>100	>100	>100
17	3.4	7.3	37.3	5.9	n.d.	18.2	>100	4.1	0.9
18	6.4	22.1	27.0	20.0	49.7	21.4	27.4	5.4	7.6
19	2.1	11.0	25.7	7.1	29.6	13.6	45.3	3.8	4.9
20	41.3	>100	>100	>100	n.d.	>100	>100	91.5	27.8
21	5.4	10.5	99.9	89.4	n.d.	>100	>100	24.7	32.0
22	4.03	>100	>100	>100	33.16	14.49	96.21	>100	14.4
23	11.0	9.5	25.1	23.3	n.d.	54.5	36.7	12.2	4.5
24	68.2	31.2	81.1	26.2	n.d.	>100	>100	32.6	>100
25	5.8	>100	>100	>100	>100	>100	>100	49.9	10.21
26	13.7	>100	>100	>100	>100	>100	>100	2.2	6.8
27	23.4	46.1	>100	50.0	n.d.	>100	>100	>100	>100
28	16.4	20.4	28.3	17.6	n.d.	41.9	65.7	28.9	21.0
29–30	>100	>100	>100	>100	>100	>100	>100	>100	>100
31	15.6	26.7	62.6	47.9	n.d.	14.9	46.3	6.5	5.3
32	9.1	20.1	53.7	57.0	n.d.	13.1	47.8	14.2	5.6
33	5.6	33.7	74.5	51.8	n.d.	16.3	42.8	12.5	4.6
34	2.4	13.3	29.6	42.6	28.7	14.4	38.5	3.5	3.7
35–37	>100	>100	>100	>100	>100	>100	>100	>100	>100
38	>100	>100	>100	>100	n.d.	>100	48.9	>100	>100
39–49	>100	>100	>100	>100	>100	>100	>100	>100	>100
50	>100	40.6	>100	>100	n.d.	>100	>100	>100	>100
52–53	>100	>100	>100	>100	n.d.	>100	>100	>100	>100
54	>100	>100	70.72	>100	>100	>100	>100	>100	>100
Etoposide	0.3	1.3	5.8	1.2	-	0.5	5.2	0.6	-
Nocodazole	0.03	0.03	0.14	0.1	-	0.02	0.04	0.1	-

ADDITIONAL RESEARCH: Compounds **19**, **34**: no DNA intercalating properties noted, no effect on microtubules noted, cell cycle arrest in G2/M phase, induction of DNA damage; EC₅₀ (PBMC) (**17–19**, **22**, **25**, **26**) = >50 μM, EC₅₀ (PBMC) (**34**) = 48.9 μM

FORCED DEGRADATION



CONCLUSION

- Mechanochemical synthesis proved to be an efficient stereoselective method for preparing the *Z*-isomer of acylhydrazone derivatives of benzo[d]oxazol-2-one.
- The majority of the tested compounds exhibited pronounced to moderate antiproliferative activity against various human tumor cell lines; the most pronounced and selective antiproliferative activity was observed for compound **17** against the *T-cell acute lymphoblastic leukemia* cell line (Molt-4, IC₅₀ = 0.9 μM).
- Stability studies under stress conditions, including hydrolytic, thermal, and oxidative degradation, showed that compound **19** was susceptible to acid and oxidative conditions and compound **30** decayed under acid and base hydrolysis, with the resulting degradation products confirmed by mass spectrometry (MS).

REFERENCES

- [1] P. Prasher, T. Mall, M. Sharma, *Arch. Pharm.* 356 (2023) 42.
- [2] L. Socea, S. Barbuceanu, E.M. Pahontu, A. Dumitru, G.M. Nitulescu, R.C. Sfetea, T. Apostol, *Molecules*, 27 (2022) 8719.

Acknowledgement

This research was conducted within the project OSKomLiMe (112104) funded by the European Union's-NextGenerationEU fund from the source 581 – The recovery and resilience mechanism, in the frame of Programme financing of public higher education institutions and public scientific institutes and the project funded Croatian Science Foundation (HRZZ-IP-2022-10-9420).

